TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ventilation Strategies, Anesthetic Techniques and Cerebral Oxygenation in the Beach Chair Position

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* scheduled for elective arthroscopic shoulder surgery in the beach chair position under general anesthesia with supplemental interscalene block~Exclusion Criteria:~* refusal to give consent~* ineligible for interscalene block~* history of cardiovascular disease~* history of cerebrovascular disease~* hypertension~* respiratory failure~* non-English speaker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Desflurane (Type: EXPERIMENTAL): Patients will receive general anesthesia with desflurane. Both arms have rSO2 measured and undergo identical changes in ventilation strategy.
- Propofol (Type: EXPERIMENTAL): Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Trypsin-Chymotrypsin On Post-operative Pain After Single Visit Root Canal Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Egyptian healthy symptomatic both gender patients~* aged (18- 40) years old~* with no physical disability, facial paresthesia or psychological problems~* had mandibular first molars with symptomatic irreversible pulpitis and with normal appearance radiographically.~Exclusion criteria:~* The vulnerable group~* participants who un abled to read and fill the questionnaire,~* those who took preoperative analgesics 24 h prior to treatment~* those with known sensitivity to the drugs used in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ibuprofen (Brufen) (Type: ACTIVE_COMPARATOR): Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
- Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) (Type: EXPERIMENTAL): Participants were handed Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
- Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) (Type: ACTIVE_COMPARATOR): Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals and Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
- Placebo pills (Sugar pills) (Type: PLACEBO_COMPARATOR): Participants were handed postoperatively sugar pills (Placebo pills) (Department of pharmaceutics \& industrial pharmacy at Faculty of pharmacy Ain Shams University, Cairo, Egypt) 3 times daily for 3 days in tightly sealed envelope with an included written paper contained the instruction for dose administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Seeking treatment for troublesome sialorrhea for at least 3 months that is occurring secondary to any disorder or related to any cause~* Investigator sites will review entire list of inclusion criteria with potential subjects~Exclusion Criteria:~* Any known prior exposure to botulinum toxin type B, or known adverse reaction or sensitivity to botulinum toxin type A, or known sensitivity to any of the MYOBLOC solution components.~* Prior botulinum toxin treatment to the salivary glands at any time~* Investigator sites will review entire list of exclusion criteria with potential subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MYOBLOC 2500 U (Type: ACTIVE_COMPARATOR): Subjects will receive specified dose of MYOBLOC
- MYOBLOC 3500 U (Type: ACTIVE_COMPARATOR): Subjects will receive specified dose of MYOBLOC
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive volume matched Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Sleep Apnea in Women Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling women Veterans aged 18 years and older~* Received care from a Veterans Health Administration (VHA) facility~* Have a least one risk factor for sleep apnea (e.g., hypertension, obesity, or age 50 years or older)~* Diagnosed as having sleep apnea with an AHI of 5 or greater~Exclusion Criteria:~* Currently using a treatment for sleep apnea~* Current pregnancy~* Active substance user or in recovery with \< 90 days of sobriety~* Too ill to engage in study procedures~* Do not have transportation to the medical center~* Unable to self-consent (e.g., due to cognitive impairment)~* Unstable housing~* Does not have sleep apnea~* Another sleep disorder (e.g., restless legs syndrome, circadian rhythm sleep disorder) accounts for sleep disturbance~* No sleep complaints or symptoms

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acceptance and the Behavioral Changes to Treat Sleep Apnea (ABC-SA) (Type: EXPERIMENTAL): Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
- Non-directive sleep apnea education control (Type: ACTIVE_COMPARATOR): Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Man or woman, 18-65 years of age, inclusive~2. Able to provide informed consent and comply with all study procedures~3. Women of childbearing potential with a negative urine pregnancy test at screening and on adequate contraception~4. Chronic, non-malignant, painful condition, treated with long-acting opioid (methadone, OxyContin®, MS (Morphine Sulfate) Contin®, Kadian®, Avinza®, Fentanyl®, Opana® ER)~5. Opioid treatment for at least 3 months prior to screening at a minimum dose of 90 mg of morphine equivalents per day or 50 mcg of the fentanyl transdermal patch~6. Dose of opioid treatment stable for at least 1 week prior to screening and expected to be stable from screening through end of second testing~7. Weight at screening 100-300 pounds, inclusive~Exclusion Criteria:~1. Pregnant or breastfeeding~2. Gastrointestinal disorder or S/P gastrointestinal surgery impacting absorption of study medication (delayed gastric emptying, partial or complete gastrectomy)~3. Alcohol or substance abuse within 2 years of screening~4. Consumption of alcohol within 24 hours of a screening or testing visit~5. Consumption of xanthine-containing beverages (coffee, tea, coke) on the morning of a screening or testing visit~6. Impaired kidney or liver function (transaminase levels more than 3 times elevated; estimated creatinine clearance less than 50 mL/min)~7. Epworth sleepiness scale (ESS) score 16 or higher at screening~8. Medically concerning hypertension (≥ 160/100) or unstable cardiovascular illness~9. Any clinically significant illness that would interfere with study participation or put the subject at risk~10. Exposure to investigational medication within 30 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Oxymorphone ER 40 mg fed (Type: EXPERIMENTAL): Participants received 40 mg oxymorphone ER after a high-fat meal of approximately 1,010 kCal
- Oxymorphone ER 40 mg fasting (Type: EXPERIMENTAL): Participants received 40 mg oxymorphone ER after fasting for 8-12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Systematic Approach to Weaning From Mechanical Ventilation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* remain in mechanical ventilation for more than 24 hours~* begin weaning from mechanical ventilation~Exclusion Criteria:~* admitted in the unit already in weaning from mechanical ventilation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Protocol-directed (Type: EXPERIMENTAL): Discontinuation of ventilation was based in multidisciplinary protocol.
- Usual care (Type: NO_INTERVENTION): Discontinuation of ventilation was left entirely to the discretion of the physicians.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must demonstrate acute psychopathologic severity criteria and be at least moderately ill.~* Patients must have experienced an exacerbation of their illness within the previous 2 weeks.~* Patients in whom a switch to another antipsychotic medication is acutely indicated.~Exclusion Criteria:~* Patients who are deemed nonresponsive to risperidone or olanzapine.~* Patients who have been hospitalized for greater than 2 weeks immediately prior to Visit 1.~* Patients having received olanzapine or risperidone in the past 30 days.~* Treatment with clozapine within 1 year prior to Visit 1.~* Diagnosis of substance-induced psychosis by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria within 7 days of Visit 1 (or at any time during the study), or confirmed on clinical grounds within 72 hours subsequent to Visit 1 (or at any time during the study).~* A diagnosis of Parkinson's disease, dementia-related psychosis, or related disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Olanzapine for Not Early Onset response (NEO) patients
- 2 (Type: ACTIVE_COMPARATOR): Risperidone for Not Early Onset response (NEO) patients
- 3 (Type: ACTIVE_COMPARATOR): Risperidone for Early Onset response (EO) patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be Hispanic~2. Must be ≥18 years~3. Must have ≥2 cardiometabolic conditions (e.g., obesity, diabetes, hypertension, dyslipidemia ischemic heart diseases, congestive heart failure, other chronic coronary conditions)~4. Must have ≥1 behavioral health concern(s) (i.e., related to mental health, life stressors, medication adherence, healthcare use)~5. Must have telephone access~Exclusion Criteria:~1. Pregnancy~2. Serious life-threatening condition with life expectancy \< 6 months~3. Psychiatric morbidity or neurological/cognitive impairment of sufficient severity to preclude participation in the intervention~4. Discharging to location other than home (e.g., nursing care)~5. Does not speak Spanish or English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Volunteer Peer Mentor + Behavioral Health Nurse
- Control (Type: NO_INTERVENTION): Care as Usual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Feasibility Device Study to Prevent Female Urinary Stress Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Urinary Incontinence Diagnosis (QUID). This questionnaire has 3 questions each referring to the seriousness of Stress Urinary Incontinence (SUI) and of Urge Urinary Incontinence (UUI). Subjects will be accepted if their SUI score is 5 or greater and is greater than the UUI score.~Exclusion Criteria:~* Refusal to sign the informed consent document~* SUI score is less than 5 or is less than the UUI score.~* Predominantly UUI~* Prolapse greater than mild~* Hysterectomy or other pelvic floor surgery other than a Caesarian section~* Diabetes,~* Pregnant,~* BMI\>35 or unable to perform ten jumping jack exercises.

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- With Yoni.Fit (Type: EXPERIMENTAL): Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
- Without Yoni.Fit (Type: EXPERIMENTAL): Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents or adults (age 16-23 years inclusive), either previously enrolled in the parent study or naïve to meningococcal vaccination.~* Female subjects were to be negative for pregnancy~Exclusion Criteria:~* History of meningococcal disease~* Receipt of any meningococcal vaccine outside of parent study (V59P6)~* Serious, acute, or chronic illnesses including HIV infection/disease and any malignancy~* receipt of any vaccine 14 days prior to the study, or expected through the duration of the study~* any condition which in the eyes of the investigator would pose a health risk to the subject or render them inappropriate for a research study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- I: MenACWY-CRM vaccine (Type: EXPERIMENTAL): Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.
- II: Licensed Polysaccharide Meningococcal vaccine (Type: EXPERIMENTAL): Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.
- III: Meningococcal Naive (Type: EXPERIMENTAL): Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic restless legs syndrome~Exclusion Criteria:~* History of sleep disturbances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed acute symptomatic DVT of the lower limbs~Exclusion Criteria:~* Severe concomitant diseases (e.g. renal failure, hepatic failure, uncontrolled hypertension)~* Active bleeding or high risk for bleeding.~* Pregnancy or childbearing potential without proper contraceptive measures.~* Breastfeeding~* Known allergy to idraparinux, SSR126517E, or egg proteins~* Indication of prolonged anticoagulation for other reason than DVT of the lower limbs~* Symptomatic pulmonary embolism (PE)~* Life expectancy \< 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idrabiotaparinux (Type: EXPERIMENTAL): Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.~In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)
- Idraparinux (Type: ACTIVE_COMPARATOR): Idraparinux sodium, 2.5 mg, once-weekly for 6 months~In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients on long-term warfarin (for prophylaxis of arterial embolism in patients with atrial fibrillation or mechanical heart valve replacement, or secondary prophylaxis after VTE) with a target INR of 2.0-3.0 or 2.5-3.5,~* Anticoagulant therapy managed by the clinic (HHS - General Hospital) for at least 6 months prior to enrolment, and~* Maintenance dose of warfarin unchanged for the previous 6 months or longer.~Exclusion Criteria:~* Age \<18 years,~* Life expectancy of less than 1 year,~* Attending physician believes the patient is not suitable for the study (e.g. psychiatric disorder, history of non-compliance),~* Geographic inaccessibility or~* Failure to obtain written consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 12-weekly INR (Type: SHAM_COMPARATOR): Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
- Standard management (Type: NO_INTERVENTION): Dosing warfarin every 4 weeks, all INRs true values

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete